Page 55 - Read Online

Page 671 Sooi et al. Cancer Drug Resist 2023;6:656-73 https://dx.doi.org/10.20517/cdr.2023.48

69. Stein MN, Fong L, Mega AE, et al. KEYNOTE-046 (Part B): effects of ADXS-PSA in combination with pembrolizumab on survival
in metastatic, castration-resistant prostate cancer patients with or without prior exposure to docetaxel. J Clin Oncol 2020;38:126.
DOI
70. Fukumura D, Kloepper J, Amoozgar Z, Duda DG, Jain RK. Enhancing cancer immunotherapy using antiangiogenics: opportunities
and challenges. Nat Rev Clin Oncol 2018;15:325-40. DOI PubMed PMC
71. Ott PA, Hodi FS, Buchbinder EI. Inhibition of immune checkpoints and vascular endothelial growth factor as combination therapy
for metastatic melanoma: an overview of rationale, preclinical evidence, and initial clinical data. Front Oncol 2015;5:202. DOI
PubMed PMC
72. Shelley M, Harrison C, Coles B, Staffurth J, Wilt TJ, Mason M. Chemotherapy for hormone-refractory prostate cancer. Cochrane
Database Syst Rev 2006;18:CD005247. DOI PubMed
73. Redman JM, Gibney GT, Atkins MB. Advances in immunotherapy for melanoma. BMC Med 2016;14:20. DOI PubMed PMC
74. Rolfo C, Caglevic C, Santarpia M, et al. Immunotherapy in NSCLC: a promising and revolutionary weapon. Adv Exp Med Biol
2017;995:97-125. DOI PubMed
75. Huang Y, Yuan J, Righi E, et al. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor
microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A 2012;109:17561-6. DOI PubMed PMC
76. Adotevi O, Pere H, Ravel P, et al. A decrease of regulatory T cells correlates with overall survival after sunitinib-based
antiangiogenic therapy in metastatic renal cancer patients. J Immunother 2010;33:991-8. DOI PubMed
77. Ko JS, Zea AH, Rini BI, et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma
patients. Clin Cancer Res 2009;15:2148-57. DOI
78. Graham DK, DeRyckere D, Davies KD, Earp HS. The TAM family: phosphatidylserine sensing receptor tyrosine kinases gone awry
in cancer. Nat Rev Cancer 2014;14:769-85. DOI PubMed
79. Lemke G, Rothlin CV. Immunobiology of the TAM receptors. Nat Rev Immunol 2008;8:327-36. DOI PubMed PMC
80. FDA Prescribing Information - Cabometyx. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/
208692s010lbl.pdf. [Last accessed on 25 Sep 2023].
81. Tripathi M, Nandana S, Billet S, et al. Modulation of cabozantinib efficacy by the prostate tumor microenvironment. Oncotarget
2017;8:87891-902. DOI PubMed PMC
82. Agarwal N, McGregor B, Maughan BL, et al. Cabozantinib in combination with atezolizumab in patients with metastatic castration-
resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021). Lancet Oncol
2022;23:899-909. DOI PubMed
83. Sharma P, Pachynski RK, Narayan V, et al. Nivolumab plus ipilimumab for metastatic castration-resistant prostate cancer:
preliminary analysis of patients in the CheckMate 650 trial. Cancer Cell 2020;38:489-99.e3. DOI PubMed
84. Joshi H, Pinski JK. Association of ARV7 expression with molecular and clinical characteristics in prostate cancer. J Clin Oncol
2016;34:109. DOI
85. Shenderov E, Boudadi K, Fu W, et al. Nivolumab plus ipilimumab, with or without enzalutamide, in AR-V7-expressing metastatic
castration-resistant prostate cancer: a phase-2 nonrandomized clinical trial. Prostate 2021;81:326-38. DOI PubMed PMC
86. Boudadi K, Suzman DL, Anagnostou V, et al. Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic
prostate cancer. Oncotarget 2018;9:28561-71. DOI PubMed PMC
87. Hotte SJ, Winquist E, Chi KN, et al. CCTG IND 232: a phase II study of durvalumab with or without tremelimumab in patients with
metastatic castration resistant prostate cancer (mCRPC). Ann Oncol 2019;30:v885. DOI
88. Aragon-Ching JB, Williams KM, Gulley JL. Impact of androgen-deprivation therapy on the immune system: implications for
combination therapy of prostate cancer. Front Biosci 2007;12:4957-71. DOI PubMed
89. Foster WR, Car BD, Shi H, et al. Drug safety is a barrier to the discovery and development of new androgen receptor antagonists.
Prostate 2011;71:480-8. DOI PubMed
+ + +
90. Page ST, Plymate SR, Bremner WJ, et al. Effect of medical castration on CD4 CD25 T cells, CD8 T cell IFN-γ expression, and
NK cells: a physiological role for testosterone and/or its metabolites. Am J Physiol Endocrinol Metab 2006;290:E856-63. DOI
PubMed
91. Gamat M, McNeel DG. Androgen deprivation and immunotherapy for the treatment of prostate cancer. Endocr Relat Cancer
2017;24:T297-310. PubMed PMC
92. Shen YC, Ghasemzadeh A, Kochel CM, et al. Combining intratumoral Treg depletion with androgen deprivation therapy (ADT):
preclinical activity in the Myc-CaP model. Prostate Cancer Prostatic Dis 2018;21:113-25. DOI PubMed PMC
93. Kissick HT, Sanda MG, Dunn LK, et al. Androgens alter T-cell immunity by inhibiting T-helper 1 differentiation. Proc Natl Acad Sci
U S A 2014;111:9887-92. DOI PubMed PMC
94. Powles T, Yuen KC, Gillessen S, et al. Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant
prostate cancer: a randomized phase 3 trial. Nat Med 2022;28:144-53. DOI PubMed PMC
95. The Cancer Genome Atlas Research Network. The molecular taxonomy of primary prostate cancer. Cell 2015;163:1011-25. DOI PubMed PMC
96. Hoimes CJ, Graff JN, Tagawa ST, et al. KEYNOTE-199 cohorts (C) 4 and 5: phase II study of pembrolizumab (pembro) plus
enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 2020;38:5543. DOI
97. Hodge JW, Garnett CT, Farsaci B, et al. Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by
cytotoxic T lymphocytes and is distinct from immunogenic cell death. Int J Cancer 2013;133:624-36. DOI PubMed PMC